PE Rolls Up Supplement Contract Manufacturers: What It Means for Your Brand
Private equity has spent the last decade consolidating gyms, studios, and fitness technology. Now it's moving deeper into the supply chain. The Riverside Company-backed Western Botanicals has acquired CSB Nutrition, a contract developer and manufacturer of vitamins, minerals, herbal products, and dietary supplements based in Spanish Fork, Utah. The deal is quiet by Wall Street standards. Its implications for branded supplement companies are anything but.
This is not an isolated transaction. It's a signal that the contract development and manufacturing organization (CDMO) layer of the supplement industry is entering a consolidation cycle that branded companies of every size need to understand and prepare for now.
Who Is Western Botanicals, and Why Does CSB Nutrition Matter?
Western Botanicals has built its reputation as a full-service supplement manufacturer, handling everything from raw material sourcing to finished product delivery. CSB Nutrition, its newest acquisition, serves brands globally across the vitamin, mineral, herbal, and dietary supplement categories. The Utah-based operation brings added capacity, an established client base, and manufacturing infrastructure that strengthens Western Botanicals' position as a one-stop CDMO partner.
Behind the deal is The Riverside Company, a private equity firm with a long track record of building businesses through strategic bolt-on acquisitions. Riverside isn't buying Western Botanicals to hold it steady. It's buying it to grow it, which means more acquisitions, more capacity aggregation, and an increasingly dominant negotiating position relative to the brands that depend on these manufacturers.
The Market These Firms Are Betting On
The economic logic here is straightforward. The global dietary supplements market is projected to reach $324.88 billion by 2034, growing at a compound annual rate of 6.37%. Several structural forces are driving that trajectory: rising health consciousness across age groups, a broad shift toward preventive healthcare, growing demand for personalized nutrition protocols, and accelerating consumer interest in plant-based and herbal supplement formats.
That last point matters specifically for brands in the sports nutrition and functional wellness space. Pea protein supports muscle growth, as recent research confirms, and consumer interest in plant-derived performance ingredients is pushing brands to reformulate and diversify their product lines. That reformulation pressure creates more demand for CDMO services, which is exactly the environment Riverside is positioning Western Botanicals to capitalize on.
When the end market is growing at 6% annually and consumer demand is becoming more complex and specialized, the manufacturers who can handle that complexity become structurally more valuable. PE firms understand this. Many branded supplement companies have not fully reckoned with what it means for them.
The Pharma Playbook, Applied to Supplements
This consolidation strategy isn't new. It follows the same pattern that reshaped pharmaceutical contract manufacturing over the past 15 years. The playbook has three phases: aggregate capacity by rolling up regional manufacturers, standardize quality and compliance systems across the acquired entities, then leverage that scale to price more aggressively and impose stricter minimum order quantities on brands that lack the volume to push back.
In pharma, this dynamic created a two-tier market. Large pharmaceutical companies with significant order volumes negotiated favorable terms. Smaller brands and emerging generics manufacturers faced higher per-unit costs, longer lead times, and reduced flexibility. There's no structural reason the supplement industry should land differently.
This mirrors what's happening at the retail and operator level in fitness more broadly. Providence Equity's acquisition of Fitness Park accelerated European gym consolidation, concentrating market leverage in the hands of a smaller number of operators. The CDMO consolidation wave in supplements operates by the same logic, just one layer deeper in the value chain.
What This Means for Emerging and Mid-Size Brands
If you're running a sports nutrition brand, a functional wellness line, or a private-label supplement business that relies on independent contract manufacturers, the Western Botanicals-CSB Nutrition deal is a direct prompt to reassess your supply-chain position.
Here's what a more consolidated CDMO market looks like in practice:
- Fewer independent manufacturing partners. As rollups continue, the number of genuinely independent CDMOs will shrink. The partners you have today may be acquisition targets tomorrow, and their new ownership may have different priorities, pricing structures, or client tier systems.
- Higher minimum order quantities. Consolidated manufacturers optimize for throughput. Smaller brands that can't commit to large production runs may find themselves pushed toward less favorable terms or deprioritized during high-demand periods.
- Lead-time pressure at peak demand. When manufacturing capacity is concentrated, peak seasonal periods, think Q4 or the January wellness surge, become bottlenecks. Brands without priority status in a PE-backed CDMO's client hierarchy will feel that pressure acutely.
- Upward pricing pressure. Scale and standardization allow consolidated CDMOs to reduce their own costs. They don't necessarily pass those savings to smaller clients. The pricing power flows to the manufacturer, not the brand.
None of this is catastrophic if you act before the market shifts further. It becomes a serious operational problem if you wait until your current manufacturer has been acquired, restructured, and repriced.
The Supply-Chain Audit You Should Be Running Right Now
The practical response to CDMO consolidation isn't panic. It's a disciplined supply-chain review. Here's where to start.
Map your single points of failure. If you're currently single-sourced with any contract manufacturer, that's a vulnerability regardless of consolidation risk. Identify every product line where you have no secondary manufacturing option and treat those as your highest-priority gaps to close.
Qualify secondary suppliers before you need them. Supplier qualification takes time. It involves sample production, stability testing, label compliance review, and often iterative formulation adjustments. Starting that process now, while your current manufacturer relationships are intact, is significantly easier than doing it under pressure after an acquisition changes your terms.
Review your contracts for change-of-control provisions. When a CDMO is acquired, your existing manufacturing agreement may or may not bind the new ownership in the ways you expect. Have a legal review of your current contracts with this specific risk in mind. Know what your rights are if ownership changes.
Build volume leverage where you can. If you have multiple product lines manufactured at the same facility, consolidating orders can improve your negotiating position with any CDMO, consolidated or independent. Volume leverage is your most effective tool in a market where manufacturers hold increasing structural power.
Stay close to formulation ownership. Brands that own their formulations and their raw material specifications retain more optionality than brands that rely on a CDMO's proprietary blends. If your current formulations are locked to a specific manufacturer's proprietary inputs, that's a dependency worth resolving while you have alternatives.
The Broader Pattern: PE Is Rewriting Fitness and Wellness Infrastructure
The supplement CDMO consolidation isn't happening in isolation. Private equity has been systematically acquiring infrastructure across the fitness and wellness ecosystem, and brands that understand that pattern can position themselves more strategically. Xponential's poison pill defense signals how competitive boutique fitness M&A has become, and the same competitive intensity is now reaching further into the supply chain.
What's consistent across these deals is that PE firms are targeting infrastructure with pricing power. CDMOs hold that pricing power because branded supplement companies need them. Gym networks hold it because fitness consumers need access points. Wearable platforms hold it because health data is increasingly central to consumer behavior. WHOOP and Ultrahuman's funding rounds show exactly where capital is concentrating in the wearable and wellness data space.
Brands that treat these as separate stories are missing the structural shift. The common thread is that PE is buying leverage over the businesses that serve end consumers. That includes the factories that make your supplements.
The Strategic Takeaway for Supplement Brands
The Western Botanicals acquisition of CSB Nutrition is a data point, not a crisis. But data points that go unacted on have a way of becoming crises when enough of them accumulate in the same direction.
The supplement brands that will navigate this consolidation wave most successfully are the ones that treat supply-chain resilience as a strategic priority rather than an operational afterthought. That means qualifying secondary manufacturers now, owning your formulations, understanding your contract terms, and building the volume relationships that give you standing in a market where CDMO pricing power is structurally increasing.
The growth projections for dietary supplements are real. The demand for plant-based, personalized, and performance-focused nutrition products is genuine and durable. But a growing end market doesn't automatically protect your margins if the manufacturing layer above you has consolidated into the hands of a few PE-backed platforms optimizing for their own returns. Know where you stand in the supply chain, and act accordingly.